{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:07:45Z","timestamp":1764022065602,"version":"3.45.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beijing Science and Technology Innovation Medical Development Foundation","award":["KC2021-ZZ-0010-8"],"award-info":[{"award-number":["KC2021-ZZ-0010-8"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10147-025-02887-y","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:51:37Z","timestamp":1760025097000},"page":"2532-2540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-HER2 plus endocrine therapy versus anti-HER2 plus chemotherapy in hormone receptor-positive and HER2-positive metastatic breast cancer: a retrospective study"],"prefix":"10.1007","volume":"30","author":[{"given":"Zhenhua","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5343-0302","authenticated-orcid":false,"given":"Xueli","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"2887_CR1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1309\/ymj3-a83t-b39m-rut9","volume":"123","author":"P Lal","year":"2005","unstructured":"Lal P, Tan LK, Chen B (2005) Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 123:541\u2013546. https:\/\/doi.org\/10.1309\/ymj3-a83t-b39m-rut9","journal-title":"Am J Clin Pathol"},{"key":"2887_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055","author":"N Howlader","year":"2014","unstructured":"Howlader N, Altekruse SF, Li CI et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/dju055","journal-title":"J Natl Cancer Inst"},{"key":"2887_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","volume":"14","author":"JS Ross","year":"2009","unstructured":"Ross JS, Slodkowska EA, Symmans WF et al (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320\u2013368. https:\/\/doi.org\/10.1634\/theoncologist.2008-0230","journal-title":"Oncologist"},{"key":"2887_CR4","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/jnci\/djh166","volume":"96","author":"J Shou","year":"2004","unstructured":"Shou J, Massarweh S, Osborne CK et al (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2\/neu cross-talk in ER\/HER2-positive breast cancer. J Natl Cancer Inst 96:926\u2013935. https:\/\/doi.org\/10.1093\/jnci\/djh166","journal-title":"J Natl Cancer Inst"},{"key":"2887_CR5","doi-asserted-by":"publisher","first-page":"7795","DOI":"10.1073\/pnas.0602468103","volume":"103","author":"W Xia","year":"2006","unstructured":"Xia W, Bacus S, Hegde P et al (2006) A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 103:7795\u20137800. https:\/\/doi.org\/10.1073\/pnas.0602468103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2887_CR6","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1158\/0008-5472.can-08-4490","volume":"69","author":"L Liu","year":"2009","unstructured":"Liu L, Greger J, Shi H et al (2009) Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 69:6871\u20136878. https:\/\/doi.org\/10.1158\/0008-5472.can-08-4490","journal-title":"Cancer Res"},{"key":"2887_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3067","volume":"13","author":"YC Wang","year":"2011","unstructured":"Wang YC, Morrison G, Gillihan R et al (2011) Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers\u2013role of estrogen receptor and HER2 reactivation. cancer res 13:R121. https:\/\/doi.org\/10.1186\/bcr3067","journal-title":"cancer res"},{"key":"2887_CR8","doi-asserted-by":"publisher","first-page":"865s","DOI":"10.1158\/1078-0432.CCR-031212","volume":"11","author":"CK Osborne","year":"2005","unstructured":"Osborne CK, Shou J, Massarweh S et al (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance. Clin cancer res 11:865s-s870. https:\/\/doi.org\/10.1158\/1078-0432.CCR-031212","journal-title":"Clin cancer res"},{"key":"2887_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ctrv.2016.03.012","volume":"46","author":"F Schettini","year":"2016","unstructured":"Schettini F, Buono G, Cardalesi C et al (2016) Hormone receptor\/Human epidermal growth factor receptor 2-positive breast cancer: where we are now and where we are going. Cancer Treat Rev 46:20\u201326. https:\/\/doi.org\/10.1016\/j.ctrv.2016.03.012","journal-title":"Cancer Treat Rev"},{"key":"2887_CR10","doi-asserted-by":"publisher","first-page":"5529","DOI":"10.1200\/jco.2008.20.6847","volume":"27","author":"B Kaufman","year":"2009","unstructured":"Kaufman B, Mackey JR, Clemens MR et al (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J clin oncol 27:5529\u20135537. https:\/\/doi.org\/10.1200\/jco.2008.20.6847","journal-title":"J clin oncol"},{"key":"2887_CR11","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1200\/jco.2009.23.3734","volume":"27","author":"S Johnston","year":"2009","unstructured":"Johnston S, Pippen J Jr, Pivot X et al (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J clin oncol 27:5538\u20135546. https:\/\/doi.org\/10.1200\/jco.2009.23.3734","journal-title":"J clin oncol"},{"key":"2887_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.breast.2011.07.006","volume":"21","author":"J Huober","year":"2012","unstructured":"Huober J, Fasching PA, Barsoum M et al (2012) Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 21:27\u201333. https:\/\/doi.org\/10.1016\/j.breast.2011.07.006","journal-title":"Breast"},{"key":"2887_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109\u2013119. https:\/\/doi.org\/10.1056\/NEJMoa1113216","journal-title":"N Engl J Med"},{"key":"2887_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/s1470-2045(13)70130-x","volume":"14","author":"SM Swain","year":"2013","unstructured":"Swain SM, Kim SB, Cort\u00e9s J et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461\u2013471. https:\/\/doi.org\/10.1016\/s1470-2045(13)70130-x","journal-title":"Lancet Oncol"},{"key":"2887_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/s1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM, Miles D, Kim SB et al (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21:519\u2013530. https:\/\/doi.org\/10.1016\/s1470-2045(19)30863-0","journal-title":"Lancet Oncol"},{"key":"2887_CR16","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1200\/jco.2017.76.7863","volume":"36","author":"M Rimawi","year":"2018","unstructured":"Rimawi M, Ferrero JM, de la Haba-Rodriguez J et al (2018) First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol 36:2826\u20132835. https:\/\/doi.org\/10.1200\/jco.2017.76.7863","journal-title":"J Clin Oncol"},{"key":"2887_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1200\/jco.20.01894","volume":"39","author":"SRD Johnston","year":"2021","unstructured":"Johnston SRD, Hegg R, Im SA et al (2021) Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE. J Clin Oncol 39:79\u201389. https:\/\/doi.org\/10.1200\/jco.20.01894","journal-title":"J Clin Oncol"},{"key":"2887_CR18","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1158\/1078-0432.ccr-21-3435","volume":"28","author":"X Hua","year":"2022","unstructured":"Hua X, Bi XW, Zhao JL et al (2022) Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for patients with hormone receptor-positive and HER2-positive metastatic breast cancer (SYSUCC-002). Clin Cancer Res 28:637\u2013645. https:\/\/doi.org\/10.1158\/1078-0432.ccr-21-3435","journal-title":"Clin Cancer Res"},{"key":"2887_CR19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/s1470-2045(20)30112-1","volume":"21","author":"SM Tolaney","year":"2020","unstructured":"Tolaney SM, Wardley AM, Zambelli S et al (2020) Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarchER): a randomised, open-label, phase 2 trial. Lancet Oncol 21:763\u2013775. https:\/\/doi.org\/10.1016\/s1470-2045(20)30112-1","journal-title":"Lancet Oncol"},{"key":"2887_CR20","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1097\/cm9.0000000000002676","volume":"136","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Zhang S, Wang T et al (2023) Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer. Chin Med J 136:1459\u20131467. https:\/\/doi.org\/10.1097\/cm9.0000000000002676","journal-title":"Chin Med J"},{"key":"2887_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10549-017-4529-5","volume":"167","author":"JA Malmgren","year":"2018","unstructured":"Malmgren JA, Mayer M, Atwood MK et al (2018) Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990\u20132010. Breast Cancer Res Treat 167:579\u2013590. https:\/\/doi.org\/10.1007\/s10549-017-4529-5","journal-title":"Breast Cancer Res Treat"},{"key":"2887_CR22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10549-014-2916-8","volume":"145","author":"DA Yardley","year":"2014","unstructured":"Yardley DA, Kaufman PA, Brufsky A et al (2014) Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Res Treat 145:725\u2013734. https:\/\/doi.org\/10.1007\/s10549-014-2916-8","journal-title":"Breast Cancer Res Treat"},{"key":"2887_CR23","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1634\/theoncologist.2019-0446","volume":"25","author":"D Tripathy","year":"2020","unstructured":"Tripathy D, Brufsky A, Cobleigh M et al (2020) De novo versus recurrent HER2-positive metastatic breast cancer: patient characteristics, treatment, and survival from the SystHERs registry. Oncologist 25:e214\u2013e222. https:\/\/doi.org\/10.1634\/theoncologist.2019-0446","journal-title":"Oncologist"},{"key":"2887_CR24","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E et al (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31:1623\u20131649. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.010","journal-title":"Ann Oncol"},{"key":"2887_CR25","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH et al (2021) ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann oncol 32:1475\u20131495. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019","journal-title":"Ann oncol"},{"key":"2887_CR26","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1158\/1078-0432.ccr-18-1131","volume":"25","author":"DR Sudhan","year":"2019","unstructured":"Sudhan DR, Schwarz LJ, Guerrero-Zotano A et al (2019) Extended adjuvant therapy with neratinib plus fulvestrant blocks ER\/HER2 crosstalk and maintains complete responses of ER(+)\/HER2(+) breast cancers: implications to the ExteNET trial. Clin cancer res 25:771\u2013783. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-1131","journal-title":"Clin cancer res"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02887-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02887-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02887-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:02:11Z","timestamp":1764021731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02887-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2887"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02887-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Ethical approval for this work was obtained from Ethics Committee of Peking University Shougang Hospital (No. IRBK-2022\u2013002-01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Informed consent was waived due to the retrospective character of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}